# US 2003/0073668 A1 · Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073668 A1
- Document ID: US20030073668A1
- Status: Published application
- Kind: A1
- Application number: 10/182,178
- Filed: 2002-07-24
- Published: 2003-04-17
- Earliest claimed: 2002-07-24
- Assignees: Warner-Lambert Company
- Inventors: Richard John Booth; Ellen Myra Dobrusin; Vara Prasad Venkata Nagendra Josyula; Dennis Joseph McNamara; Peter Laurence Toogood
- Web page: https://patentgrep.com/patent/US20030073668A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds of the formula (I) wherein: R2, R7, RI3, R14 and R15 are independently hydrogen, or (un)substituted lower alkyl, (un)substitued lower alkenyl, (un)substituted lower alkynyl, or (un)substituted —(CH2)nR12; R5 is halogen, cyano, nitro, —R9, —NR9R10, or —OR9; R6 is halogen, cyano, nitro, —R9, —NR9R10, —OR9, —Co2R9, —COR9, —CONR9R10, —NR9COR10, (un)substiuted lower alkenyl, or (un)substituted lower alkynyl; R8 is —CO2R13, —COR13, —CONR13R14, —CSNR13R14, —C(NR13)NR14R15, —SO3R13, —SO2R13, —SO2NR13R14, —PO3R13R14, —POR13R14, —PO(NR13R14)2; R9 and R10 are independently hydrogen or (un)substituted lower alkyl; R11 is a heteroaryl or a heterocyclic group; R12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group; and n is 0,1,2, or 3. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor-mediated kinases.

## Claims

### Claim 1

A compound of the Formula I
13
and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:
R2, R7, R13, R14, and R15 are independently hydrogen, or lower alkyl, lower alkenyl, or lower alkynyl, each of which is optionally substituted with up to 5 groups independently selected from halogen, cyano, nitro, —R9, —NR9R10, —OR9, —(CH2)nCO2R9, —(CH—))nSO2R11, —(CH—)nR11, —COR9, —CONR9R10, —SO3R9, —SO2NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or a heterocycle optionally substituted with up to 3 groups independently selected from —R9, —NR9R10, —OR9, —NR9COR10, —COR10, —(CH2)nSO2R11, —(CH2)nR11 or
—(CH—))R12 optionally substituted with up to 5 groups independently selected from halolen, cyano, nitro, —R9, —NR9R10, —OR9, —(CH2)nCO2R9, —(CH2)nSO2R11, —(CH2)nR11, —COR9, —CONR9R10, —SO3R9, —SO2NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2 R10, —NR9CONR9R10, —NR9SO2R10, or a heterocycle optionally, substituted with up to 3 groups independently selected from —R9, —NR9R10, —OR9, —NR9COR10, —COR10, —(CH2)nSO2R11, —(CH2)nR11;
R5 is halogen, cyano, nitro, —R9, —NR9R1 °, or —OR9;
R6 is halogen, cyano, nitro, —R9, —NR9R10, —OR9, —CO2R9, —COR9, —CONR9R10, —NR9COR10, —SO2NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, or lower alkenyl or lower alkynyl optionally substituted with —R9;
R8 is H, —CO2R13, —COR13, —CONR13R14, —CSNR13R14, —C(NR13)NR14R15, —SO3R13, —SO2R13, —SO2NR13R14, —PO3R13R14, —POR13R14,—PO(NR13R14)2;
R9 and R10 are independently hydrogen, or lower alkyl, optionally substituted with up to 3 groups selected from the group consisting of halogen, amino, mono- or dialklylamino, hydroxy, lower alkoxy, phenyl or substituted phenyl,
or when taken together with the nitrogen to which they are attached. R9 and R10 form a ring having from 3-7 members, up to four of which may be selected from
14
O, S, and NR20, where R20 is hydrogen, lower alkyl, or —CO lower alkyl;
R11 is a heteroaryl or a heterocyclic group;
R12 is a cycloalklyl, a heterocyclic, an ayl, or a heteroaryl group; and
n is 0, 1, 2, or 3.

### Claim 2

A compound of the Formula II
15
and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:
R7, R13, R14, and R15 are independently hydrogen, or lower alkyl, lower alkenyl, or lower alkynyl, each of which is optionally substituted with up to 5 groups independently selected from halogen, cyano, nitro, —R9, —NR9R10, —OR9, —(CH2)nCO2R9, —(CH—))nSO2R11, —(CH2)nR11, —COR9, —CONR9R10, —SO3R9, —SO2NR9R 10, —SO2R9, —SR9, —PO3R9R10 —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10 —NR9CONR9R10 —NR9SO2R10, or a heterocycle optionally substituted wvith up to 3 groups independently selected from —R9, —NR9R10, —OR9, —(CH2)nSOR11, —(CH2)nR11, or
—(CH2)nR12 optionally substituted with up to 5 groups independently selected from halogen, cyano, nitro, —R9, —NR9R10, —OR9, —(CH2)nCO2R9, —(CH2)nSO2R11, —(CH2)nR11, —COR9, —CONR9R10, —SO3R9, —SO2NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR 10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or
a heterocycle optionally substituted with up to 3 groups independently selected from —R9 —NR9R10, —OR9, —(CH2)nSO2R11, —(CH2)nR11,
R5 is halogen, cyano, nitro, —R9, —NR9R10, or —OR9;
R6 is halogen, cyano, nitro, —R9, —NR9R10, —OR9, —CO2R9, —COR9, —CONR9R10, —NR9COR10, or lower alkenyl or lower alkynyl optionally substituted with —R9;
R8 is H, —CO2R13, —COR13, —CONR13R14, —CSNR13R14, —C(NR13)NR14R15, —SO3R13, —SO2R13, —SO2NR13R14, —PO3R13R14, —POR13R14, —PO(NR13R14)2;
R9 and R10 are independentls hydrogen, or lower alkyl, optionally substituted with up to 3 groups selected from the group consisting of halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxyl, phenyl or substituted phenyl,
or when taken together uwith the nitrogen to which they are attached, R9 and R10 form a ring having from 3-7 members, up to four of which mav be selected from
16
, O, S, and NR20, where R20 is hydrogen, lower alkyl, or —CO lower alkyl;
R11 is a heteroaryl or a heterocyclic group;
R12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group;
n is 0, 1, 2, or 3; and
R16, R17, and R18 are independently hydrogen, halogen, amino, mono- or dialkylamino, hydroxy, lower alkyl, lower alkoxy, cyano, nitro, carboxy, carboxyalkyl, aminocarbonyl, mono- or dialkyilaminocarbonyl, alkylcarbonyl, —SO3R9, —SO—NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO—R10; or
R16 is a carbocyclic group containing from 3-7 members, up to 2 of which members are heteroatoms selected from oxygen and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with 1, 2, or 3 groups independently selected from the group consisting of halogen, hydroxy, lower alkyl, trifluoromethyl, lower alkoxy, amino, mono- or dialkylamino, aryl, heteroaryl, arylalkyl, heteroarylalklyl, heteroarylsulfonyl, heteroarylsulfonylalkyl, heterocyclylalkyl, heterocyclylsulfonyl, or heterocyclylsulfonylalkyl.

### Claim 3

A compound of the Formula III
17
and pharmaceutically acceptable salts, esters, amides, and prodrucs thereof, wherein:
R2 is hydrogen, or lower alkyl, lower alkenyl, or lower alkynyl, each of which is optionally substituted with up to 5 groups independently selected from halogen, cyano, nitro, —R9, —NR9R10, —OR9, —(CH2))nCO2R9, —(CH2)nSO2R11, —(CH—2)nR11, —COR9, —CONR9R 10, —SO3 R9, —SO2NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or a heterocycle optionally substituted with up to 3 groups independently selected from —R9, —NR9R10, —OR9, —(CH2)nSO2R11, —(CH2)nR11, or
—(CH2)nR12 optionally substituted with up to 5 groups independently selected from halogen, cyano, nitro, —R9, —NR9R10, —OR9, —(CH2)nCO2R9, —(CH2)nSO2R11, —(CH2)nR11, —COR9, —CONR9R10, —SO3R9, —SO—NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO—R10, or
a heterocycle optionally substituted with up to 3 groups independently, selected from —R9, —NR9R10, —OR9, —(CH2)nSO2R11, —(CH2)nR11;
R5 is halogen, cyano, nitro, —R9, —NR9R10, or —OR9;
R6 is halogen, cyano, nitro, —R9, —NR9R10, —OR9, —CO2R9, —COR9, —CONR9R10, —NR9COR10, —SO2NR9R10, —SO2R9, —SO3R9, SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, or lower alkenyl or lower alkynyl optionally, substituted with —R9;
R9 and R10 are independently hydrogen, or lower alkyl, optionally substituted with up to 3 groups selected from the group consisting, of halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, phenyl or substituted phenyl,
or when taken together with the nitrogen to which they are attached, R9 and R10 form a ring having from 3-7 members, up to four of which may be selected from
18
, O, S, and NR20, where R20 is hydrogen, lower alkyl, or —CO lower alkyl;
R11 is a heteroaryl or a heterocyclic group;
R12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group;
n is 0, 1, 2, or 3; and
R19 is hydrogen, or
lower alkyl, lower alkenyl, or lower alklynyl, each of which is optionally substituted with up to 5 groups independently selected from halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, cyano, nitro, carboxy, carboxyalkyl aminocarbonyl, mono- or dialklyaminocarbonyl, lower alkylcarbonyl, —SO3R9, —SO2NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or
aryl, heteroaryl, arylalklyl, heteroanrlalkyl, cycloalkyl or cycloalkyl-alkyl, where each aryl, heteroaryl or cycloalkyl group is optionally substituted with up to 5 groups independently selected from halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, cyano, nitro, carboxy, carboxyalkyl, aminocarbonyl, mono- or dialklylaminocarbonyl, alkylcarbonyl, —SO3R9, —SO2R9R10, —SO—NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or
a (CH2)n- carbocyclic group containing from 3-7 members, up to 2 of which members are heteroatoms selected from oxygen and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with 1, 2, or 3 groups independently selected from the group consisting of halogen, hydroxy, lower alkyl, trifluoromethyl, lower alkoxy, amino, mono- or dialkylamino, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heteroarylsulfonyl, heteroarylsulfonylalkyl, heterocyclylalkyl, heterocyclylsulfonyl, or heterocyclylsulfonylalkyl; and
R21 is hydrogen, lower alkyl, or lower alkyl substituted with phenyl or substituted phenyl.

### Claim 4

A compound of the Formula IV
19
and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:
R5 is halogen, cyano, nitro, —R9, —NR9R10, or —OR9;
R6 is halogen, cyano, nitro, —R9, —NR9R10, —OR9, —CO—R9, —COR9, —CONR9R10, —NR9COR10, —SO—R9R10, —SO2R9, —SO3R9, SR9, —PO3R9R10, POR9R10, —PO(NR9R10)2, or lower alkenyl or lower alkvnyl optionally substituted with —R9;
R9 and R10 are independently hydrogen, or lower alkyl optionally substituted with up to 3 groups selected from the group consisting of halogen, amino, mono- or dialkylamino, hydroxy lower alkoxy, phenyl or substituted phenyl, or when taken together with the nitrogen to which they are attached, R9 and R10 form a ring having from 3-7 members, up to four of which may be selected from
20
, O, S, and NR20, where R20 is hydrogen, lower alkyl, or —CO lower alkyl;
R11 is heteroaryl or a heterocyclic group;
R16, R17, and R18 are independently selected from halogen, cyano, nitro, —R9, —NR9R10, —OR9, —(CH2)nCO2R9, —(CH2)nSO2R11, —(CH2)nR11, —COR9, —CONR9R10, —SO3R9, —SO—NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or
a heterocycle optionally substituted with up to 3 groups independently selected from —R9, —NR9R10, —OR9, —NR9COR10, —COR10, —(CH2)nSO2R11, —(CH2)nR11;
R19 is hydrogen, or
lower alkyl, lower alkenyl, or lower alkynyl, each of which is optionally substituted with up to 5 groups independently selected from halogen- amino, mono- or dialkylamino, hydroxy, lower alkoxy, cyano, nitro, carboxy, carboxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, lower alkylcarbonyl, —SO3R9, —SO2NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or
aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl or cycloalkyl-alkyl, where each aryl, heteroaryl or cycloalkyl group is optionally substituted with up to 5 groups independently selected from halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, cyano, nitro, carboxy, carboxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, alkylcarbonyl, —SO3R9, —SOR9R10, —SO2NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or
a (CH2)n- carbocyclic group containing from 3-7 members, up to 2 of which members are heteroatoms selected from oxygen and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with 1, 2, or 3 groups independently selected from the group consisting of halogen, hydroxy, lower alkyl, trifluoromethyl, lower alkoxy, amino, mono- or dialkylamino, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heteroarylsulfonyl, heteroarylsulfonylalkyl, heterocyclylalkyl, heterocyclylsulfonyl, or heterocyclylsulfonylalkyl; and
R21 is hydrogen, lower alkyl, or lower alkyl substituted with phenyl or substituted phenyl.

### Claim 5

A compound of the Formula V
21
and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof: wherein:
R5 is halogen, cyano, nitro, —R9, —NR9R10, or —OR9;
R6 is halogen, cyano, nitro, —R9, —NR9R10, —OR9, —CO2R9, —COR9, —CONR9R10, —NR9COR10, —SO2NR9R10, —SO2R9, —SO3R9, SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, or lower alkenyl or lower alkynyl optionally substituted with —R9;
R16, R17, and R18 are independently selected from hydrogen, halogen, cyano, nitro, —R9, —NR9R10, —OR9, —(CH2)nCO2R9, —(CH2)nSO2R11, —(CH2)nR11, —COR9, —CONR9R10, —SO3R9, —SO2NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or
a heterocycle optionally substituted with up to 3 groups independently selected from —R9 —NR9R10, —OR9, —NR9COR10, —COR10, (CH2)nSO2R11, —(CH2)nR11;
R9 and R10 are independently hydrogen, or lower alkyl optionally substituted with up to 3 groups selected from the group consisting of halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, phenyl or substituted phenyl,
or when taken together with the nitrogen to which they are attached, R9 and R10 form a ring having from 3-7 members, up to four of which may be selected from
22
O, S, and NR20, where R20 is hydrogen, lower alkyl, or —CO lower alkyl;
R11 is heteroaryl or a heterocyclic group;
R19 is hydrogen, or
lower alkyl, lower alkenyl, or lower alkynyl, each of which is optionally substituted with up to 5 groups independently selected from halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, cyano, nitro, carboxy, carboxyalkyl aminocarbonyl, mono- or dialkylaminocarbonyl, lower alkyicarbonyl, —SO3R9, —SONR9R10, —SO2R9, —SR9, —PO3 R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or
aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl or cycloalkyl-alkyl, where each aryl, heteroaryl or cycloalkyl group is optionally substituted with up to 5 groups independently selected from halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, cyano, nitro, carboxy, carboxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, alkylcarbonyl, —SO3R9, —SO2R9R10, —SO—NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or
a (CH2)n- carbocyclic group containing from 3-7 members, up to 2 of which members are heteroatoms selected from oxygen and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with 1, 2, or 3 groups independently selected from the group consisting of halogen- hydroxy, lower alkyl, trifluoromethyl, lower alkoxy, amino, mono- or dialklylamino, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heteroanylsulfonyl, heteroarylsulfonylalkyl, heterocyclylalkyl, heterocyclylsulfonyl, or heterocyclylsulfonylalkyl; and
R21 is hydrogen, lower alkyl, or lower alklyl substituted with phenyl or substituted phenyl.

### Claim 6

A compound of Formula VI
23
and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof; wherein:
R5 is halogen, cyano, nitro, —R9, —NR9R10, or —OR9;
R6 is halogen, cyano, nitro, —R9, —NR9R10, —OR9, —CO2R9, —COR9, —CONR9R10, —NR9COR10, —SO2NR9R10, —SO2R9, —SO3R9, SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, or lower alkenyl or lower alkynyl optionally substituted with —R9;
R17 and R18 are independently selected from halogen, cyano, nitro, —R9, —NR9R10, —OR9, —(CH2)nCO2R9, —(CH2)nSO2)R11, —(CH2)nR11, —COR9, —CONR9R10, —SO3R9, —SO2NR9R10, —SO2R9, —SR9, —PO3R9R10, —POR9R10, —PO(NR9R10)2, —NR9COR10, —NR9CO2R10, —NR9CONR9R10, —NR9SO2R10, or a heterocycle optionally substituted with up to 3 groups independently selected from —R9, —NR9R10, —OR9, —NR9COR10, —COR10, —(CH2)nSO2R11, —(CH2)nR11;
R22 and R23 independently are hydrogen or alkyl

### Claim 7

A compound selected from:
1-tert-Butyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido [2,3-d]pyrimidin-7-yl]-urea;
1-tert-Butyl-3-[2-(3-chloro-4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrmidin-7-yl]-urea;
1-tert-Butyl-3-[6-fluoro-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-tert-Butyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-tert-butyl-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-3-chloro-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-tert-butyl-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-3-tert-butyl-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-5-methyl-pyrido[2,3-d]pyrimidin-7-yl}-3-tert-butyl-urea;
1-Cyclohexyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-[2-(3-Chloro-4-piperazin-1-yl-phenylamino )-pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexyl-urea;
1-Cyclohexyl-3-[6-fluoro-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Cyclohexyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-cyclohexyl-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl )-3-chloro-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-cyclohexyl-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl )-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-3-cyclohexyl-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl )-phenylamino]-5-methyl-pyrido[2,3-d]pyrimidin-7-yl}-3-cyclohexyl-urea;
1-(2-Hydroxy-ethyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-[2-(3-Chloro4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3 -(2-hydroxy-ethyl)-urea;
1-[6-Fluoro-2-(4-piperazin-1-yl)-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-(2-hydroxy-ethyl )-urea;
1-(2-Hydroxy-ethyl)-3 -[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3 -d]pyrimidin-7-yl]-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-(2-hydroxy-ethyl)-urea;
1- {2-[4-(4-Acetyl-piperazin-1-yl)-3-chloro-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-(2-hydroxy-ethyl)-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-3-(2-hydroxy-ethyl)-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-5-methyl-pyrido[2,3-d]pyrimidin-7-yl}-3-(2-hydroxy-ethyl)-urea;
1-Ethyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-[2-(3-Chloro-4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-ethyl-urea;
1-Ethyl-3-[6-fluoro-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3)-d]pyrimidin-7-yl]-urea;
1-Ethyl-3-[5-methyl-2-(4-piperazin-1-yl-pheniylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-ethyl-urea;
1-{2- [4-(4-Acetyl-piperazin-1-yl)-3-chloro-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-ethyl-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-3-ethyl-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-5-methyl-pyrido[2,3-d]pyrimidin-7-yl}-3-ethyl-urea;
1-tert-Butyl-3-(2-phenylamino-pyrido[2,3-d]pyri midin-7-yl)-urea;
1-tert-Butyl-3-[2-(4-fluoro-3-methyl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-(4-Chloro-phenyl)-3-[2-(4-fluoro-3-methyl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Isopropyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea;
1-Cyclohexyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea;
1-Cyclopentyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrinmdin-7-yl]-urea;
1-Cyclohexyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl }-urea;
1-Cyclopentyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrdo[2,3-d]pyrimdin-7-yl]-urea;
1-Cyclohexyl-3-[6-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrmidin-7-yl]-urea;
1-Cyclohexyl-3-[6-bromo-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Cyclohexyl-3-[6-cyano-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Cyclohexyl-3-[6-chloro-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Cyclohexyl-3-[6-fluoro-5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Cyclohexyl-3-[6-bromo-5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Cyclohexyl-3-[6-chloro-5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Isopropyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Ethyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-[5-Methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Methyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Cyclohexyl-1-methyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-(4-Hydroxy-cyclohexyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-(4-Amino-cyclohexyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrdo[2,3-d]pyrimidin-7-yl]-urea;
1-(2-Dimethylamino-ethyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3 -d]pyrimidin-7-yl]-urea;
1(3-Morpholino4-yl-propyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
3-Cyclohexyl-1-methyl-1-[2-(4-piperazin-1-yl-phenylamino)-pyrdo[2,3-d]pyrimidin-7-yl]-urea;
N,N-Dimethyl-N′-[5-methyl-2-[[4-(1-piperazinyl)phenyl]-amino]-pyrido[2,3-d]pyrimidin-7-y-]-sulfamide;
1-Cyclohexyl-3-[-5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-thiourea;
N-[2-(4-Piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-acetamide;
4-[7-(3-Cyclohexyl-ureido)-pyrido[2,3-d]pyrimidin-2-ylamino]-benzenesulfonamide;
1-Cyclohexyl-3-{2 -[4-(1-piperazin-1-yl-methanoyl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea;
1-Cyclohexyl-3-[9-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-(2-{4-[4-(2-Amino-4-methyl-pentanoyl)-piperazin-1-yl]-phenylamino}-pyrido[2,3-d]pyrimidin-7-yl)-3-cyclohexyl-urea; and
1-(2-{4-[4-(2-Amino-3-methyl-butanoyl)-piperazin-1-yl]-phenylamino}-pyrido[2,3-d]pyrimidin-7-yl)-3-cyclohexexyl-urea.

### Claim 8

A compound selected from:
1-tert-Butyl-3-[2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Cyclohexyl-3-[2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Ethyl-3-[2-(pyridin-4-ylamino)-pyrido[-2,3-d]pyrimidin-7-yl]-urea;
1-(Hydroxy-ethyl)-3-[2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-tert-Butyl-3-[6-fluoro-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Cyclohexyl-3-[6-fluoro-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Ethyl-3-[6-fluoro-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-[6-Fluoro-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-(2-hydroxy-ethyl )-urea;
1 -tert-Butyl-3-[5-methyl-2-(pyridin-4-ylamino)-pyrido[2,3-d]prrimidin-7-yl]-urea;
1-Cyclohexyl-3-[5-methyl-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Ethyl-[5-methyl-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea; and
1-(2-Hydroxy-ethyl)-3-[-5-methyl-2 -(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea.

### Claim 9

A compound selected from:
4-{4-[7-(3-tert-Butyl-ureido)-pyrido[2,3-d]pyrimidin-2-ylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester;
4-{4-[7-3-Cyclohexyl-ureido)-pyrido[2,3-d]pyrimidin-9-ylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester;
1-(3 -Hydroxy-propyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrdo[2,3-d]pyrimidin-7-yl]-urea;
1-((S)-1-Hydroxymethyl-3 -methyl-butyl )-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
4-Methyl-piperazine-1-carboxylic acid [2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-amide;
Morpholine-4-carboxylic acid [2-(4-piperazin-1-y1-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-amide;
3-[2-(4-Piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-1,1-dipropyl urea;
Piperazine-1-carboxylic acid [2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-amide;
1-((R)-1-Hydroxymethyl-2-methyl-propyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1,1 -Bis-(2-hydroxy-ethyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-[6-Bromo-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea;
1-[6-Bromo-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-methyl-urea;
1-{6-Bromo-2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-tert-butyl-urea;
1-{6-Bromo-2-[4-( cis-3,5-dimethyl-piperazin-1-yl )-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-cylclohexyl-urea;
1-[2-(4-Fluoro-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-(3-morpholin4-yl-propyl )-urea;
1-[2-(4-Fluoro-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl-]3-(2-hydroxy-ethyl)-urea;
1-(2-Amino-ethyl)-3-[2-(4-fluoro-phenylamino)-pnrido[2,3-d]pyrimidin-7-yl]-urea;
1-(2-Dimethylamino-ethyl)-3-[2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-Cyclohexyl-3-{2-[4-(3,3-dimethyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-urea;
1-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-urea;
1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-(3-morpholin4-yl-propyl)-urea;
1-tert-Butyl-3-{6-chloro-2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl}-urea;
3-Cyclohexyl-1-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenlylamino]-pyrido[2,3-d]pyrimidin-7-yl}-1-methyl-urea;
3-Cyclohexyl-1-ethyl-1-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
3-tert-Butyl-1-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-1-ethyl-urea;
1-[5-Methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-propyl-urea;
7-(3-tert-Butyl-ureido)-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester;
1-[6-Fluoro-5-methyl -2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-isopropyl-urea;
1-Cyclohexyl-3-{2-[4-(3,3-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea;
1-Cyclohexyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylaminol-6-methyl-pyrido[2,3-d]pyrimidin-7-yl}-urea;
1-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-methyl-pyrido[2,3-d]pyrimidin-7-yl}-urea;
1-tert-Butyl-3-[6-methyl-2-(4-piperazin-1-yl)-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;
1-{2-[4-(cis-3,5-Dimethyl-piperazin-1-yl)-phenylamino]-6-methyl-pyrdo[2,3-d]pyrimidin-7-yl}-3-isopropyl-urea;
1-Cyclopropyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1)-phenylamino]-6-methyl-pyrido[2,3-d]pyrimidin-7-yl}-urea; and
1-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-ethy]-pyrido[2,3-d]pyrimidin-7-yl}-urea.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a compound selected from claim 1 admixed with a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 11 (depends on 1)

A method for controlling proliferative disorders selected from the group consisting of cancer, psoriasis, vascular smooth muscle proliferation associated with a disorder selected from the group consisting of atherosclerosis, postsurgical vascular stenosis, and restenosis in mammals comprising administrating to said mammal a therapeutically effective amount of a compound according to claim 1.

### Claim 12 (depends on 1)

A method of inhibiting a cdk enzyme comprising contacting the cdk enzyme with a compound selected from claim 1.

### Claim 13 (depends on 12)

A method of claim 12 wherein said cdk is cdk1.

### Claim 14 (depends on 12)

A method of claim 12 wherein said cdk is cdk2.

### Claim 15 (depends on 12)

A method of claim 12 wherein said cdk is cdk4.

### Claim 16 (depends on 1)

A method of inhibiting a growth factor-mediated tyrosine kinase comprising contacting said growth factor-mediated kinase with a compound selected from claim 1.

### Claim 17 (depends on 16)

A method of claim 16 wherein said growth factor-mediated tyrosine kinase is platelet derived growth factor (PDGF).

### Claim 18 (depends on 16)

A method of claim 16 wherein said growth factor-mediated tyrosine kinase is fibroblast growth factor (FGF).

### Claim 19 (depends on 1)

A method of treating a subject suffering from diseases caused by vascular smooth muscle cell proliferation comprising administering to said subject a therapeutically effective amount of a compound selected from claim 1.

### Claim 20 (depends on 1)

A method of treating a subject suffering from cancer comprising administering to said subject a therapeutically effective amount of a compound selected from claim 1.

### Claim 21 (depends on 1)

A method of treating a subject suffering from a cancer related from breast cancer, large cell carcinoma, pancreas, colon, melanoma, lung, and leukemia comprising administering to said subject a therapeutically effective amount of a compound selected from claim 1.
